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1. Introduction 
Hodgkin’s lymphoma is a lymphoid neoplasm first described by Thomas Hodgkin in 1832 
and subsequently by Samuel Wilks in 1865 (1,2). Greenfield (1878), Sternberg (1879) and 
Reed (1902) are credited with the earliest descriptions of the pathological characteristics of 
the disease (3,4,5). In has now become clear that the Reed-Sternberg cell is derived from 
clonal B-cells, more specifically post-germinal center B-cells, giving credence to the 
malignant nature of the disease, and hence the preferred term of Hodgkin’s lymphoma –HL, 
instead of Hodgkin’s disease (6). 
Major and striking advances have been made in the biology and management of HL. More 
than 70% of patients with HL are curable (especially those presenting with early stage 
disease). Better insight has been gained with regard to the acute and long term toxicities of 
chemotherapy and radiotherapy. Furthermore, the advent of new imaging techniques such 
as PET (positron emission tomography)-scans are allowing therapy to be individualized and 
tailored in a risk adapted and response adapted fashion (7). 
The  incidence of HL varies widely throughout the world (approximately 1-3.5/100 000), 
based on geographical and ethnic factors. The highest rates of HL are seen in the United 
States, Canada and Europe, with much lower rates occurring in Japan, Korea and China. HL 
is more common in males compared to females, with a male to female ratio of 1.5:1. HL 
occurs most often in young adults, with a peak frequency in the third decade of life. A 
bimodal age distribution may be seen, with a second age peak noted in the 6th to 8th decades 
(8,9,10,11). 
The exact aetiology of HL is unknown. An increased risk of HL is seen with Epstein-Barr 
Virus (EBV) infection, congenital and acquired immunodeficiency states (such as Human 
Immunodeficiency Virus – HIV infection/AIDS- Acquired Immunodeficiency Syndrome, 
 
Immunodeficiency 
 
296 
post solid organ and haematopoietic stem cell transplantation) and  autoimmune disease 
(12-18). There is also an increased risk of familial aggregation of HL (19). 
HIV infection is known to be associated with an increased risk of HL, based on linkage and 
cohort studies. The relative risk is now 10-15 fold higher compared with the general 
population (13-15,17,18,20-22). This review will focus on HL in southern Africa, and 
describe the differences compared to HL in developed countries, highlighting the emerging 
increase in HL in the HIV seropositive population/people living with HIV/AIDS (PWHA). 
2. General aspects of HIV lymphoma 
Lymphomas are known to occur with an increased frequency in PWHA (20,21,23). NHL 
(Non-Hodgkin’s Lymphoma) is the commonest malignancy in the post cART (combination 
antiretroviral therapy) era in PWHA. The incidence of NHL in resource-rich settings has 
decreased in the post cART era compared to the pre cART era (23-24). However, the 
contrary is true in resource-poor settings, with a noticeable increase in NHL incidence (24-
26). This is particularly true of sub-Saharan Africa - the epicenter of the HIV pandemic. The 
increase in NHL incidence is due mainly to the high prevalence and heavy burden of HIV in 
sub-Saharan Africa, a region in which two thirds of PWHA reside, and additionally, in 
many countries in sub-Saharan Africa, there has been a lack of availability of, or delay in 
initiation of cART. In South Africa, which is home to over 5 million PWHA, the rollout of 
cART occurred in 2004, 8 years  later than in the Western world (introduced in developing 
countries during the end of 1996 and the beginning of 1997) and until recently, cART was 
generally only available to individuals with CD4 counts of <200/ul. Although this practice 
has changed in the last two years, with access/availability of cART to individuals with a 
higher CD4 count of <350/ul, the burden of diseases related to the immunodeficiency state 
(with notable exceptions such as Kaposi’s sarcoma) appear to be on the increase 
(17,25,26,27). 
In Africa, the HIV/AIDS epidemic was first reported in 1984 (28). The major risk of HIV in 
Africa occurs in/with heterosexual relationships, and accounts for an approximately equal 
male to female ratio, as compared to the Western world in which the major risk groups 
involve intravenous drug use and homosexual relationships, thus predominantly affecting 
males. Furthermore, early in the HIV epidemic, there was no marked increase in the 
incidence of NHL compared to the USA. This was attributed to PWHA dying earlier in the 
course of their disease possibly from infectious complications such as pneumonia and 
tuberculosis. The decreased longevity prevented the subsequent or later development of 
NHL. In addition, there may be underreporting of lymphoma or the missed diagnosis of 
lymphoma, with a diagnosis of an infective cause of lymphadenopathy (such as 
tuberculosis) being favoured over lymphoma, in the absence of performing a fine needle 
aspirate or lymph node biopsy (28-30).  
At Chris Hani Baragwanath Academic Hospital (CHBAH) – a tertiary, public sector, 
University of the Witwatersrand linked hospital located in Soweto, Johannesburg, studies in 
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the 1990’s with respect to HIV-NHL showed only a modest increase of NHL in seropositive 
individuals, with an odds ratio of 4.8, 5 and 5.9 respectively (31-33). The first patient at this 
hospital with HIV-NHL was seen in 1993. Since then, there has been a steady increase in 
HIV-NHL up to 2000. However,  since 2001, the percentage seropositivity of NHL has 
exceeded 50% (approximately between 60 – 80%), and since 2002, there has additionally 
been a significant  increase in the total number of patients diagnosed with NHL at CHBAH 
(from 20-30 new patients per year to 70-80 patients per year) (see Table 1 and Figure 1) (25). 
Indeed, NHL is now the commonest haematological malignancy in South Africa, in the 
current HIV/AIDS era and the number of seropositive  patients continues to increase. 
With respect to Hodgkin’s lymphoma (HL), the data is less dramatic, but is becoming more 
significant. In a study by Stein et al, 2008 (33), the percentage seropositivity of HL in a South 
African cohort (which included patients from CHBAH) was 19.5% (OR=1.6, 95% CI=1.0-2.7), 
during the period 1995-2004. The first patient with HIV-HL was seen in 1994 at CHBAH. 
Since then, there has been a modest increase in HIV-HL up to 2006. However, in the last 5 
years (2007 - 2011) at our single institution,  the percentage seropositivity is greater than 50% 
(see Figure 2) and the number of patients over the years are gradually increasing (doubled 
compared to an earlier series in the late 1980’s and early 1990’s – (17,34)(see  Figure 3). Thus, 
the focus of this review relates to the emerging problem of Hodgkin’s lymphoma in the 
setting of HIV in southern Africa.  
 
Year Total Number 
of Patients 
Number of 
Seronegative 
Patients 
Number of 
Seropositive 
Patients 
% Seropositive 
1993 20 19 1 5% 
1994 20 18 2 10% 
1995 18 15 3 16.7% 
1996 28 25 3 10.7% 
1997 18 14 4 22.2% 
1998 34 18 16 47.1% 
1999 22 14 8 36.4% 
2000 30 16 14 46.7% 
2001 24 4 20 83.3% 
2002 40 15 25 62.5% 
2003 44 17 27 61.4% 
2004 58 23 35 60.3% 
2005 54 15 39 72.2% 
2006 72 17 55 76.4% 
2007 72 19 53 73.6% 
2008 76 10 66 86.8% 
Table 1. Patients with non-Hodgkin’s Lymphoma seen at Chris Hani Baragwanath Academic Hospital 
from 1993 to 2008 
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Figure 1. HIV seropositive and HIV seronegative patients with non-Hodgkin’s Lymphoma from 1993 
to 2008 seen at Chris Hani Baragwanath Academic Hospital 
 
 
Figure 2. HIV seropositive and HIV seronegative patients with Hodgkin’s Lymphoma from 1990 to 
2011 seen at Chris Hani Baragwanath Academic Hospital 
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Figure 3. Total number of patients with Hodgkin’s Lymphoma seen at Chris Hani Baragwanath 
Academic Hospital from 1990 - 2011 
3. Hodgkin’s lymphoma and HIV 
3.1. Introduction and epidemiology 
HL occurring in the setting of immunodeficiency (with particular reference to HIV/AIDS) is 
generally aggressive, presents with advanced stage disease, frequent constitutional (‘B’) 
symptoms, less favourable histology, more frequent bone marrow involvement and a poorer 
prognosis compared to immunocompetent individuals (17,18). 
With the advent of HAART (highly active antiretroviral therapy), now referred to as cART 
(combination antiretroviral therapy),  the AIDS related morbidity, particularly with respect 
to opportunistic infections has decreased and the survival of HIV/AIDS patients has 
increased (35,36). In the post cART era, ADCs (AIDS-defining cancers) continue to fall, but 
the rates of NADCs (non-AIDS defining cancers) such as HL, anal  carcinoma, lung 
carcinoma and skin cancers are on the increase (37). With HL, there  is a noticeably  
increasing relative risk of approximately 10 - 15 fold, compared with the general population 
(13-15,17,18,20-22).  
Several epidemiological studies conducted in the last two decades, and summarised in the 
article by Carbone et al, 2009 (22) strongly support the evidence that HIV positive 
individuals have a higher risk of developing HL compared to their HIV negative 
counterparts. This is in contrast to HIV-NHL or HIV-Kaposi’s sarcoma (where the incidence 
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of the disease has decreased significantly after the introduction of cART). cART has allowed 
the use of standard therapeutic options to be delivered to seropositive patients in a more 
optimal manner, bringing about renewed optimism in the management of such patients. 
cART  use is associated with higher CD4 T cell counts and enhanced immunity. Thus, 
despite the benefit of cART, which improves immunity and decreases the risk of 
opportunistic infections, there is a paradoxical increased risk of HL (22). The authors 
conclude that the improved CD4 T cell count that occurs post cART use, provides anti-
apoptotic pathways and mechanisms for immune escape by tumour cells, thus resulting in 
an increased risk of HL (22). 
However, in contrast to this, a 20-year cohort study has shown that with the advent of 
antiretroviral therapy, ADCs (AIDS-defining cancers) continue to fall, but the rates of 
NADCs (non-AIDS defining cancers) are on the increase. The authors suggest that this 
increase appears to be more related to the aging of the HIV population (i.e. increased 
longevity allowing a greater risk of developing lymphoma) rather than the antiretroviral 
therapy and its effect on the CD4 T cell count (37).  
3.2. Pathogenesis 
Histologically, HL is characterized by a population of neoplastic Reed-Sternberg (RS) cells, 
which constitute <1-2% of the cellular component, admixed with a reactive, mixed 
inflammatory infiltrate of lymphocytes, plasma cells, eosinophils and histiocytes. Cytokines 
and chemokines are produced by either the RS cells or the reactive cells in the background 
micro-environment of the tissue. The cytokine production may explain the presence and 
maintenance of an impaired immune response, while the chemokines (cytokines with 
chemoattractant properties) play a role in leucocyte trafficking, attract chemokine receptor 
CCR4-expressing Th-2 cells and T regulatory cells,  and allow a favourable environment for 
survival of RS cells (38-40). Cross talk between the RS cells and reactive cells mediated by 
cytokines such as IL-13, IL-17, IL-10, transforming growth factor-beta and chemokines - 
principally CCL17 (thymus and activation-regulated chemokine, TARC) and CCL22 
(macrophage-derived chemokine, MDC),  lead to an environment where RS cells are able to 
proliferate, escape from apoptosis and survive host anti-tumour defense (38-40). The CD4+ T 
cells surrounding the neoplastic cells in HL are CD45RO+/CD45RA-/CD45RBdim, suggesting 
a memory Th2 phenotype (41). 
HIV-associated immunosuppression is a state that permits the unchecked and uncontrolled 
proliferation of Epstein-Barr virus (EBV) infection. EBV has been implicated in the 
etiopathogenesis of classic HL, with a high frequency of EBV association (80-100%) noted in 
tissues of patients with HIV-HL (42,43). EBV transforming proteins, such as latent 
membrane protein-1 (LMP-1), is expressed in virtually all HIV-HL patients (43-45). The 
expression of EBV-LMP-1 is important in the pathogenesis of HIV-HL. LMP-1 expression by 
EBV-infected RS cells represents the principal mechanism for constitutive NF (nuclear 
factor) -κB activity, which confers an apoptosis resistant phenotype to the RS cells (43,45). 
EBV-immortalized B cells also produce CCL17 and CCL22 through LMP-1 mediated 
activation of NFκB (46).  
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RS cells of classical HL represent transformed B cells (post germinal center B cells) that 
originate from preapoptotic germinal center B cells. They express CD15 and CD30 as well as  
LMP-1 and display a BCL6-/CD138+/MUM1/IRF4+ (Interferon Regulatory Factor-4) 
phenotype (43,47,48). In addition, LMP2A and EBNA-1 may also contribute to the 
development of the RS cells and are expressed in the RS cells of this tumour (44,45). LMP2A 
may promote the survival of the ‘crippled’ germinal center B cells, thereby aiding in their 
development (49).  
3.3. Clinical presentation and management 
In general, HIV-seropositive patients with HL tend to have a more aggressive clinical  
course than their seronegative counterparts. The behaviour of the disease is different, and 
based on a number of studies (22,50-57), the following characteristics were noted: more 
frequent constitutional ‘B’ symptoms – 70-96%, more advanced stage disease (III and IV) – 
74-92%, , more frequent involvement of extranodal sites – 17-62%, with bone marrow 
involvement being the most common extranodal site – 40-59%, followed by involvement of 
the liver – 17-40% and spleen – 20-30%. The vast majority (>80%) of the patients were males. 
The median age at presentation was approximately 34 years. The median CD4 count was 
mostly in the intermediate range of 240-306/µl (22,50-57). Compared to HIV negative HL, 
where nodular sclerosis is the dominant histological subtype, mixed cellularity is most 
commonly encountered in HIV-HL – 33-53% (17,22,34,56-57). Nodular sclerosis is the second 
most common histological subtype in HIV-HL – 24-31%. However, with more severe 
immunosuppression, nodular sclerosis becomes infrequent (38). There is also an increasing 
number of patients with lymphocyte depleted histology - 14-20% in HIV-HL (17,22,56-57). 
Based on the Italian Cooperative Group on AIDS and Tumors (GICAT) study, in 
comparison with patients who were cART naive, patients receiving cART before the onset of 
HL are older, have less B symptoms, have higher leukocyte and neutrophil counts and have 
a higher haemoglobin level (56). 
In a recent review of 43 patients with HIV associated HL seen at CHBAH over a 2 year 
period (July 2008 – June 2010) a number of striking similarities and differences were noted 
when comparing this cohort with other published studies outside of Africa (17). The median 
age at presentation of 38 years was similar to other series. There was no striking male 
predominance. Conversely, the male to female ratio is almost equal at 1.1:1. All the patients 
had heterosexual acquisition of HIV. None of the patients acquired their HIV through 
intravenous drug use or homosexual contacts. This is different to other series where 
homosexuality and intravenous drug use are significant, documented risk groups 
(15,20,22,50,56,57). The presentation with advanced stage disease (82%), more frequent ‘B’ 
symptoms (93%), more frequent involvement of extranodal sites (bone marrow-38%; liver-
45%; spleen-28%) and ‘true’ extranodal sites (17%) and the histological pattern of disease 
(mixed cellularity being the most common) is similar to that reported in the literature. The 
median CD4 count of 176/µl is generally lower, although there are series reported of HIV-
HL with median CD4 counts of <200/µl (51). In this series 12/29 (41%) of the  patients had 
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newly diagnosed HIV at the time of the diagnosis of HL. In 62% of the patients, the duration 
of the diagnosis of HIV (including new patients was < 1 year). Only 45% of the patients were 
on antiretroviral therapy at diagnosis of HL, compared to 71-80% in other series (22,56,57). 
A further striking difference is the high proportion of patients with Tuberculosis in this 
series – 59% (38% with active disease and 21% with past, documented disease). The high 
prevalence of tuberculosis may be a reflection of the more severe immunosuppression in the 
patients, the delay in diagnosis of HIV and hence the absence of antiretroviral therapy use at 
diagnosis and the very common occurrence of tuberculosis in the general population. The 
presence of tuberculosis, often in a disseminated fashion, has an adverse impact on the 
clinical outcome of the patients. In general, the outcome of the HIV-HL patients was less 
favourable than the HIV seronegative patients (17). 
In another local study from CHBAH, covering a fifteen period from 1990 to 2004, the clinical 
characteristics of 163 patients with Hodgkin’s lymphoma are reviewed (58). Table 2 depicts 
the differences between the HIV seropositive and HIV seronegative patients in this study. 
 
HIV Status Seropositive Seronegative 
Total Number of Patients = 163 47 (29%) 116 (71%) 
Median Age (Range) in Years 30 (13-59) 29 (13-87) 
M:F Ratio 1.8:1 1.2:1 
CD4 Count at Presentation (/ul) 186 (32-769) N/A 
‘B’ Symptoms 77% 78% 
Advanced Stage (III & IV) Disease 78% 67% 
‘True’ Extranodal Disease 13% 12% 
Histological Subtype: 
Mixed Cellularity 
Nodular Sclerosis 
Other 
 
61% 
17% 
22% 
 
42% 
41% 
13% 
Tuberculosis 
Prevalence 
Active Disease 
 
27% 
19% 
 
23% 
17% 
Treatment Response 
Complete Response 
Partial Response 
 
38% 
8% 
 
57% 
21% 
Table 2. Clinical characteristics of HIV seropositive and HIV seronegative patients seen over a fifteen 
year period (1990 - 2004) at Chris Hani Baragwanath Academic Hospital (adapted from Fazel, 2012) 
Based on the findings of this study, HIV seronegative patients compared to HIV 
seropositive patients have more advanced stage disease, a higher frequency of mixed 
cellularity subtype, a slightly higher risk of tuberculosis and ‘true’ extranodal disease and a 
poorer response to treatment (58).  
The management of HIV-HL is challenging because of the frequency of infections, likelihood 
of organ dysfunction due to HIV, more frequent involvement of the bone marrow, increased 
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myelosuppression, potential drug-drug interactions of the antiretrovirals and anti-infectives 
with chemotherapy, the advanced and widespread nature of the disease at presentation and 
the preponderance of less favourable histological subtypes. Treatment approaches include 
vigorous supportive care (HAART, antivirals, antifungals, neutrophil-stimulating growth 
factors), together with standard multiagent chemotherapy.  
Chemotherapy regimens for HIV-HL such as EBV, EBVP, ABVD and MOPP/ABV hybrid are 
feasible and can be delivered with concomitant cART. The AIDS Clinical Trials Group 
(ACTG) treated 21 patients with ABVD for 4-6 cycles with G-CSF support. Antiretroviral 
therapy was not used. The complete remission rate (CR) was 43% with a median overall 
survival of 18 months (59). In a more recent Spanish study (GESIDA – Groupo de Estudia de 
SIDA), 62 patients with HIV-HL received the standard, full-dose  ABVD and cART with 87% 
of the patients achieving a CR. The 5-year overall survival (OS) and event-free survival 
(EFS) probabilities were 76 and 71% respectively. The immunological response to HAART 
had a positive impact on OS (p=0.002) and EFS (p=0.001) (60). Use of cART substantially 
improves the overall survival in HIV associated HL. This is due to a decrease in the 
incidence of opportunistic infections, the ability to deliver more appropriate and aggressive 
chemotherapy on schedule and to the less aggressive presentation of lymphoma in patients 
on cART, in comparison with those lymphomas that arise in patients who never received 
cART (50-53). In the study of Hentrich et al, 2006, 34/59 patients receiving cART (n=34) had a 
significantly better 2-year overall survival than those not receiving cART (74% versus 30%, 
p<0.001) (61). The advent of cART also allows for more aggressive treatment options such as 
VEBEP (62), BEACOPP (63), Stanford V (64) and the use of high-dose chemotherapy and 
autologous stem cell transplantation (ASCT) in selected patients (65,66). However, in 
general, response rates and cure rates are lower than in HIV seronegative patients, despite 
the substantial progress made in the last decade. The challenge at present is to optimise the 
use of standard approaches as used in HIV negative HL. Once this is established, evaluation 
of experimental and newer therapies should follow. 
4. Conclusion 
HIV is associated with an increased risk of developing HL, a risk that has not lessened 
despite the introduction and benefit of cART. HL is now being regarded among the most 
common NADCs, which have clearly increased in the post cART era. The association from 
being largely coincidental (overlapping and similar age group for both HL and HIV)  may 
now be increasingly causal, with the most plausible explanation being attributed to the 
pathogenetic role of Epstein Barr virus infection. 
The recognition of an increasing trend of HIV-HL in resource-poor settings needs to be 
further highlighted, so that early diagnosis, early recourse to cART and appropriate 
supportive therapy and specific therapy such as chemotherapy can be administered to 
improve survival.  
Therapy of HIV associated HL entails using the same therapeutic approaches as in 
seronegative HL, including standard chemotherapy regimens such as ABVD, and in the 
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salvage setting, autologous stem cell transplantation in selected patients. In general, the 
prognosis and overall survival still remains poorer in HIV-HL compared to HIV negative 
HL. Importantly, the concomitant use of anti-retroviral agents has allowed for the delivery 
of full-dose and dose-intensive chemotherapy given on schedule, as well as prophylaxis 
against certain opportunistic infections such as Pneumocystis jirovecii pneumonia, and the 
liberal use of growth factors (granulocyte colony stimulating factor) and other supportive 
measures, constitutes an important aspect of supportive therapy and has contributed to an 
improvement in prognosis. The early recognition and treatment of tuberculosis cannot be 
overemphasized in settings where tuberculosis is endemic. Newer specific treatment 
approaches for HL may become  necessary in the future to improve survival. However, for 
the present, HIV-associated HL appears to be on the increase and remains an emerging and 
ongoing challenge. 
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